Wall Street analyst estimates for Celldex Therapeutics, Inc. (CLDX): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase.
Consensus price target
$66.80 (+125% vs price $29.71)
between $45.00 and $100.00 · 12 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $1.7M | $32,610 – $4.9M | -$4.13 | 8 |
| 2027E | $8.8M | $3.8M – $13.7M | -$4.23 | 8 |
| 2028E | $123M | $10.3M – $257M | -$3.41 | 9 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 16 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 20 |
| Avg rating (−2 sell to +2 buy) | 0.80 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-09 | $-1.02 | ||
| 2026-08-06 | $-0.94 | $-1.06 | +11.3% |
| 2026-05-07 | $-1.18 | $-1.15 | -2.9% |
| 2026-02-25 | $-1.22 | $-1.00 | -22.0% |
| 2025-11-10 | $-1.01 | $-0.88 | -14.8% |
| 2025-08-07 | $-0.85 | $-0.86 | +1.2% |
| 2025-05-08 | $-0.81 | $-0.75 | -8.0% |
| 2025-02-27 | $-0.71 | $-0.73 | +2.7% |
Valuation Ratios
| Price / Book | 3.24 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.8M | $12.7M | $9.5M | $3.6M | $7.4M | $4.7M | $2.4M | $6.9M | $7.0M | $1.5M |
| Cost of Revenue | $102.0M | $96.2M | $66.4M | $42.7M | $42.5M | $53.3M | $82.3M | $118.0M | $163.6M | 0 |
| Gross Profit | -$95.2M | -$83.4M | -$56.9M | -$39.1M | -$35.1M | -$48.7M | -$79.9M | -$111.1M | -$156.5M | $1.5M |
| Research & Development | $102.7M | $96.2M | $66.4M | $42.7M | $40.5M | $56.8M | $82.3M | $118.0M | $163.6M | $245.1M |
| Selling, General & Admin | $36.0M | $25.0M | $19.3M | $15.4M | $14.5M | $20.5M | $27.2M | $30.9M | $38.5M | $43.8M |
| Operating Expenses | $37.7M | $38.1M | $99.5M | $15.9M | $28.2M | $22.6M | $35.3M | $43.4M | $38.5M | $288.9M |
| Operating Income | -$132.9M | -$121.5M | -$156.4M | -$55.0M | -$63.4M | -$71.2M | -$115.2M | -$154.5M | -$195.1M | -$287.4M |
| EBITDA | -$124.4M | -$104.0M | -$72.6M | -$49.7M | -$45.6M | -$66.1M | -$104.2M | -$139.0M | -$154.7M | -$255.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$128.5M | -$117.3M | -$151.9M | -$50.9M | -$60.9M | -$70.7M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| Income Tax | 0 | -$24.3M | -$765,000 | 0 | -$1.2M | -$226,999 | 0 | 0 | 0 | 0 |
| Net Income | -$128.5M | -$93.0M | -$151.2M | -$50.9M | -$59.8M | -$70.5M | -$112.3M | -$141.4M | -$157.9M | -$258.8M |
| EPS | -$18.99 | -$10.86 | -$14.48 | -$3.51 | -$2.02 | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
| EPS (Diluted) | -$18.99 | -$10.86 | -$14.48 | -$3.51 | -$2.02 | -$1.64 | -$2.40 | -$2.92 | -$2.45 | -$3.90 |
| Shares Outstanding (Diluted) | 6.8 M | 8.6 M | 10.4 M | 14.5 M | 29.6 M | 42.9 M | 46.9 M | 48.4 M | 64.4 M | 66.5 M |
Price
| Price | $29.71 (closing price, November 3, 2026) |
| Market Cap | $2.3B |
| Exchange | NASDAQ |
| Country | US |
Related companies: IMNM · NRIX · XNCR · RCUS
Explore sector: Healthcare · Biotechnology
More sections of CLDX: Overview · Financials · Valuation · Technical · Ownership
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks